SR33805

SR33805 is a potent Ca 2+ channel antagonist, with EC 50 s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca 2+ channels. SR33805 can be used for the research of acute or chronic failing heartsIn VitroSR33805 (0.01-10 µM; 3 d) inhibits growth factor-induced proliferation of SMC (0.20 50<0.46 µM) in a dose-dependent manner. SR33805 (10 µM; 10 min) restores the myocardial infarction (MI)-altered cell shortening without affecting the Ca 2+ transient amplitude. SR33805 (10 µM) decreases the activity of recombinant PKA. Cell Viability AssayCell Line: Smooth muscle cells (SMC) Concentration: 0.01, 0.1, 1, 10 µM Incubation Time: 3 days Result: Inhibited in a dose-dependent manner FCS-, bFGF and PDGF-induced proliferation of porcine SMC with IC 50 s of 0.26±0.08, 0.46±0.1 and 0.20±0.04 µM, respectively.In VivoSR33805 (20 mg/kg; a single i.p.) improves end-systolic strain and fractional shortening of MI hearts in rats. SR33805 (5 mg/kg/day; p.o. for 38 d) significantly reduces intimal hyperplasia in pigs. Animal Model: Male Wistar rats (5 weeks) are subjected to coronary artery ligatureDosage: 0.2, 2, 20 mg/kg Administration: A single i.p. injection Result: Increased significantly both end-systolic strain (ESS) and fractional shortening (FS) by about +38 and +26%, respectively at the dose of 20 mg/kg. Did not affect other contractile parameters.Form:SolidIC50& Target:L-type calcium channel 4.1 nM (EC 50 , in depolarized conditions) L-type calcium channel 33 nM (EC 50 , in polarized conditions)

Specifications & Purity: SR33805 is a potent Ca 2+ channel antagonist, with EC 50 s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca 2+ channels. SR33805 can be used for the research of acute or chronic failing heartsIn VitroSR33805 (0.01-10 µM; 3 d) inhibits growth factor-induced proliferation of SMC (0.20 50<0.46 µM) in a dose-dependent manner. SR33805 (10 µM; 10 min) restores the myocardial infarction (MI)-altered cell shortening without affecting the Ca 2+ transient amplitude. SR33805 (10 µM) decreases the activity of recombinant PKA. Cell Viability AssayCell Line: Smooth muscle cells (SMC) Concentration: 0.01, 0.1, 1, 10 µM Incubation Time: 3 days Result: Inhibited in a dose-dependent manner FCS-, bFGF and PDGF-induced proliferation of porcine SMC with IC 50 s of 0.26±0.08, 0.46±0.1 and 0.20±0.04 µM, respectively.In VivoSR33805 (20 mg/kg; a single i.p.) improves end-systolic strain and fractional shortening of MI hearts in rats. SR33805 (5 mg/kg/day; p.o. for 38 d) significantly reduces intimal hyperplasia in pigs. Animal Model: Male Wistar rats (5 weeks) are subjected to coronary artery ligatureDosage: 0.2, 2, 20 mg/kg Administration: A single i.p. injection Result: Increased significantly both end-systolic strain (ESS) and fractional shortening (FS) by about +38 and +26%, respectively at the dose of 20 mg/kg. Did not affect other contractile parameters.Form:SolidIC50& Target:L-type calcium channel 4.1 nM (EC 50 , in depolarized conditions) L-type calcium channel 33 nM (EC 50 , in polarized conditions)

Grade: Moligand™

Molecular Formula: C32H40N2O5S

Molecular Weight: 564.74

PubChem CID: 129426

Isomeric SMILES: CC(C)C1=C(C2=CC=CC=C2N1C)S(=O)(=O)C3=CC=C(C=C3)OCCCN(C)CCC4=CC(=C(C=C4)OC)OC

Storage Temperature: Store at -20°C

Shipped in: Ice chest + Ice pads

UPC:

51442306

Weight:

1.06 Ounces

HazmatClass:

Yes

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

S648296-25mg

Country of Origin:

China

CAS:

121345-64-0

Product Size:

25mg

Harmonized Tariff Code:

2931.90.90